Please ensure Javascript is enabled for purposes of website accessibility

Why Shares of Celldex Therapeutics, Inc. Sailed Higher Today

By Keith Speights – Nov 1, 2018 at 3:51PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The clinical-stage biotech received a spark from excitement over the release of abstracts to be presented at a major conference.

What happened

Shares of Celldex Therapeutics, Inc. (CLDX -1.17%) sailed 11.8% higher as of 3:22 p.m. EDT on Thursday. The most likely reason driving Celldex's nice gain is the rising tide for biotech stocks in general thanks to the release of abstracts to be presented at the American Society of Hematology (ASH) 2018 meeting in December.

Celldex isn't presenting at ASH this year but, scientists from Emory University are scheduled to present data from research involving the biotech's pipeline candidate CDX-301. This research was partially funded by Celldex.

Three scientists working in a lab and writing things down.

Image source: Getty Images.

So what

Celldex's jump today reflected improving sentiment for the beaten-down biotech industry a lot more than it did anything new for the company itself. The one abstract featuring Celldex's CDX-301 was only a preclinical study conducted on mice. The data from the research could be promising for Celldex -- but it's still really early.

Microcap stocks like Celldex Therapeutics are likely to experience relatively big swings both up and down based on broader market movements. That's especially the case when other biotech stocks are also moving up or down significantly. For example, Celldex's share price sank last week on no news at all other than other biotechs presenting at the European Society of Medical Oncology's annual meeting.

Investors can pretty much ignore these kinds of gains and losses. If Celldex had presented terrific data from one of its clinical studies of varlilumab, CDX-301, CDX-1140, or CDX-3379 at a major conference -- or even terrible data -- it would be something to seriously evaluate. But that's not what's going on, so today's move is basically noise.

Now what

Celldex does have a lot of activity going on. It's conducting an ongoing phase 1 study of CDX-1140. The company said in its Q2 update that enrollment of a study of CDX-1140 in combination with CDX-301 would begin in September. Celldex should also be close to completing enrollment in the first part of its phase 2 combo study of CDX-3379 and Lilly's Erbitux in treating advanced head and neck squamous cell carcinoma.

Investors will want to keep their ears and eyes open for progress on all of these fronts. Celldex should provide an update when it reports its third-quarter results in the next few weeks.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Celldex Therapeutics. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Celldex Therapeutics, Inc. Stock Quote
Celldex Therapeutics, Inc.
$27.78 (-1.17%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.